GleamWall
中文EN

AARD Aardvark Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1774857 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-49.2%
TTM EPS YoY22.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-80.9%
ROA-73.5%
ROIC (approx.)-149.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets11.1%
Debt / equity0.00x
Current ratio9.11x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0—
R&D expense$15.67M$10.46M$16.57M$14.30M$13.74M$13.14M$7.75M$8.06M
SG&A expense$4.05M$4.63M$5.90M$4.41M$3.97M$2.70M$2.71M$1.39M
Operating income-$19.72M-$15.08M-$22.46M-$18.70M-$17.70M-$15.85M-$10.47M-$9.45M
Net income-$19.19M-$14.39M-$21.59M-$17.60M-$16.32M-$14.37M-$9.31M-$8.78M
EBITDA-$19.71M-$15.07M-$22.45M-$18.69M-$17.69M-$15.84M-$10.46M-$9.44M
EPS (basic)-0.88-0.66-0.99—-0.75-0.66-0.71—
EPS (diluted)-0.88-0.66-0.99—-0.75-0.66-0.71—
Weighted avg. shares (diluted)21.89M21.85M21.82M—21.71M21.69M13.19M—
Balance sheet
Cash & equivalents$60.34M$73.85M$62.44M$47.05M$39.28M$26.00M$26.50M$61.64M
Short-term investments$13,000$21,000$28.76M$62.98M$87.06M$115.82M$124.76M$12.02M
Current assets$64.11M$80.66M$93.58M$111.89M$129.21M$144.77M$154.55M$74.14M
Total assets$64.80M$81.46M$98.59M$117.18M$133.23M$147.47M$157.03M$77.51M
Current liabilities$7.03M$6.39M$11.60M$10.55M$10.74M$10.31M$5.98M$4.93M
Total liabilities$7.19M$6.66M$11.60M$10.55M$10.85M$10.55M$6.34M$5.39M
Shareholders' equity$57.61M$74.80M$86.99M$106.63M$122.38M$136.93M$150.69M-$54.64M
Shares outstanding21.89M21.88M21.82M21.82M21.75M21.69M21.69M4.07M
Cash flow statement
Operating cash flow-$13.54M-$17.60M-$18.87M-$16.81M-$16.13M-$9.84M-$11.39M-$7.73M
Capital expenditure$0——$0$4,000$91,000$0$6,000
Free cash flow-$13.54M——-$16.81M-$16.13M-$9.94M-$11.39M-$7.73M
Investing cash flow$0$28.75M$34.25M$24.30M$29.25M$9.41M-$112.62M-$11.89M
Financing cash flow$22,000$262,000$4,000$274,000$171,000-$71,000$88.88M-$1.01M
Depreciation & amortization$10,000$11,000$11,000$10,000$10,000$11,000$5,000$8,000
Stock-based compensation$1.97M$1.95M$2.00M$1.58M$1.50M$634,000$233,000$173,000

Free plan shows the latest 8 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.